aBeijing Key Laboratory of Cell & Gene Therapy for Solid Tumour, State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Department of Early Drug Development Centre, ...

In this article, we present the case of a patient with sigmoid cancer T3N1M0 and rectal cancer T2N0M0 who started postoperative chemotherapy according to the XELOX (CAPOX) regimen (oxaliplatin with ...

In the 260-patient study, median event-free survival reached 16 months for patients assigned to PAXG, as compared with 10.2 months with the mFOLFIRINOX (5-fluorouracil, leucovorin, irinotecan ...

Ernexa Therapeutics’ “Trojan Horse” stem cells can infiltrate ovarian tumors in mice, boosting T cell activity and leading to shrunken tumors and improved survival, the company announced in ...

Amgen has detailed a positive phase 3 readout for its T-cell engager Imdelltra in previously treated small cell lung cancer (SCLC). The DLL3xCD3 bispecific has shown that it can help patients live ...

Tarlatamab, a bispecific delta-like ligand 3–directed T-cell engager immunotherapy, received accelerated approval for the treatment of patients with previously treated small-cell lung cancer.

CHICAGO, June 1 (Reuters) - A Gilead Sciences-backed therapy made with a patient's own white blood cells shrank tumors in 62% of patients with recurrent glioblastoma, a rare event for a fatal ...

Final results of the phase 3 CASSANDRA trial (NCT04793932) demonstrated that PAXG (cisplatin, nab-paclitaxel, gemcitabine, and capecitabine) is superior to modified FOLFIRINOX (mFOLFIRINOX) as ...

CHICAGO — For patients with pancreatic resectable stage I-Ill pancreatic ductal adenocarcinoma (PDAC), neoadjuvant chemotherapy can help improve overall survival compared with upfront surgery.

In a phase 3, randomized trial, we enrolled patients with local or regional cutaneous squamous-cell carcinoma, after surgical resection and postoperative radiotherapy, at high risk for recurrence ...